GFM1 and cancer: Furthermore, genetic variants in CHD1L, GFM1, MEIS1 and NFX1 have previously been reported in other cancer types (the type of genetic variant was not specified) but at lower frequency than reported here, such as genetic variants in CHD1L for 10% of primary CNS lymphomas, GFM1 for 5.7% of cholangiocarcinomas, MEIS1 for 5.7% of uterine carcinosarcomas, and NFX1 for 6.7% of malignant peripheral nerve sheath tumors [20].